


 Cite this: *RSC Adv.*, 2018, **8**, 10333

# Preparation, *in vitro* and *in vivo* evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK)<sup>†</sup>

Yu Fang, <sup>ab</sup> Dawei Wang,<sup>a</sup> Xingyu Xu,<sup>a</sup> Gila Dava,<sup>a</sup> Jianping Liu,<sup>a</sup> Xiang Li,<sup>a</sup> Qianqian Xue,<sup>a</sup> Huan Wang,<sup>a</sup> Jiangshan Zhang<sup>b</sup> and Huabei Zhang<sup>\*a</sup>

Focal adhesion kinase (FAK) has been identified as a promising target in the early diagnosis and therapy of tumor. In this work, we obtained and evaluated another two novel pyrimidine-based F-18 labeled tumor imaging agents targeting FAK. Among them, the corresponding F-19 standards [<sup>19</sup>F]2, displayed inhibition of FAK with IC<sub>50</sub> values of 57.1 nM (better than the results in our published work) and showed an good selectivity profile against some other kinds of cancer-related kinases. [<sup>18</sup>F]2 also had relatively good results in the *in vivo* biodistribution in S180-tumor-bearing mice, with tumor uptake of 5.40 ± 0.12 and 5.96 ± 0.09 % ID per g at 15 and 30 min post-injection, respectively. What's more, [<sup>18</sup>F]2 could be accumulated in tumor at 30 min post-injection, which could be observed from the coronal micro-PET images of mice bearing S180 tumor. In addition, the blocking study for the [<sup>18</sup>F]2 with PF-562271 (one of the well-known best selective FAK inhibitor), displayed distinct reduction in the uptake of the radiotracer in tumor at 30 min post-injection in mice, suggesting that the uptake of [<sup>18</sup>F]2 in tumor was due to FAK over-expression or high expression in tumor. And the results of the molecular dynamics (MD) simulations and the docking studies were in consistent with the changing trends of the interaction between the F-19 standards and the FAK. Finally, in order to further increase the uptake of the F-18 labeled tracer in tumor, the following points should arouse attention, which could also be considered as the new findings and contributions of this study to the field of the tumor imaging agents: (1) the F-18 labeled tumor radiotracers which have closer interaction with the FAK, should be further designed, *via* building of models such as 3D-QSAR model to make reasonable guidance to our drug design and consideration of some functional groups which have hydrogen-bonding or salt-bridge interactions with key residues in the kinase domain of FAK; (2) the F-18 radiotracers with better pharmacokinetic properties should be designed, *via* building of dynamic drug absorption and distribution model in different tissues, to predict whether the molecules have ideal absorption in tumor and low uptake in non-target tissues. The relevant study is being undertaken.

Received 22nd January 2018  
 Accepted 6th March 2018

DOI: 10.1039/c8ra00652k  
[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

Functional molecular imaging on the basis of radiotracers (imaging agents), has facilitated the diagnosis and

management of illnesses such as cancer, heart diseases and brain disorders. PET/CT and SPECT/CT based on the radiotracers are subfields of nuclear imaging. They can identify disease state at an early stage of development of disease, often before symptoms occur or abnormalities can be detected with other tests such as X-ray, NMR and CT.

Among them, PET/CT based on the positron isotope (such as F-18) labeled radiotracers, is the most sensitive imaging method recognized by modern medical field, which is of great significance for the early diagnosis, staging, prognosis judgment and treatment plan of cancer. PET/CT on the basis of <sup>18</sup>F-FDG is most widely used in clinical diagnosis and evaluation of cancer. However, this kind of radiotracer has fatal drawbacks. For example, its high accumulation in inflamed and infected tissues can lead to false-positive results and its low uptake in

<sup>a</sup>Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, People's Republic of China. E-mail: [hbzhang@bnu.edu.cn](mailto:hbzhang@bnu.edu.cn); Tel: +86-10-58822012

<sup>b</sup>College of Chemistry and Chemical Engineering, Anyang Normal University, No. 436 Xian'ge Avenue, Anyang 455000, People's Republic of China

<sup>†</sup> Electronic supplementary information (ESI) available: <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, <sup>19</sup>F-NMR and ESI-MS spectra for some key intermediates and target compounds, the chemical structures of [<sup>19</sup>F]1 and [<sup>18</sup>F]1, and the biodistribution data of [<sup>18</sup>F]1-[<sup>18</sup>F]3 and so on, were included in the supplementary material. See DOI: 10.1039/c8ra00652k.



tumors that are growing slowly can cause false-negative results. Therefore, there is an urgent need to develop new PET radio-tracers with obvious targeting and tissue specificity for tumor.

Focal Adhesion Kinase (FAK), a kind of non-receptor tyrosine kinase,<sup>1,2</sup> has been considered to be a pivotal pathogenic mediator of various diseases. Among them, cancer is the most widely studied disease.<sup>3</sup> Many evidence has suggested that FAK participates in a variety of biological behaviors of tumor, with its over-expression or high expression in the vast majority of types of tumor cells.<sup>3-21</sup> In addition, FAK over-expression or high expression has been shown to be correlated with worse outcome in most kinds of cancer patients with hepatocellular carcinoma, invasive breast carcinoma, intestinal-type gastric carcinoma, endometrial cancer, acute myeloid leukemia, anaplastic astrocytoma tumor, sarcoma (such as osteosarcoma), ovarian carcinoma, neuroblastoma, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma and so on.<sup>19-21</sup>

Therefore, people have developed many FAK inhibitors as anti-neoplastic drugs, among which some even in clinical phase II trial. By and large, small molecular FAK inhibitors fall into two categories:<sup>20,22,23</sup> inhibitors which bind to the ATP-binding site,<sup>4,5,24-28</sup> and inhibitors targeting the scaffolding function of FAK.<sup>29-31</sup>

However, as far as we know, most of all of the previous studies were just focused on the research of FAK inhibitors for the tumor therapy at the level of generic pharmaceuticals, except for the only two recent reports by our research group which were first dedicated to the development of FAK-targeted radiotracers for tumor imaging on the radiopharmaceutical level.<sup>22,23</sup> In this work, we obtained another two F-18 labeled novel 5-bromo-*N*<sup>2</sup>-(4-(2-fluoro-pegylated (FPEG))phenyl)-*N*<sup>4</sup>-(4-methoxy-phenyl)-pyrimidine-2,4-diamine analogues and evaluated them as tumor imaging agents targeting FAK, in order to make some comparison with our previous work in the bioactivity of the radiotracers, where the left side chain of the target compounds changed from “4-(2-fluoro-pegylated (FPEG))-3,5-dimethoxyphenyl” in one of our previous reports<sup>22</sup> to “4-(2-fluoro-pegylated (FPEG))phenyl”, and the FPEG chain on the left side of the target compounds changed from *n* = 1 in another one of our previous reports<sup>23</sup> to *n* = 2 & *n* = 3 here.

## 2. Experimental

### 2.1. General remarks

All chemicals and reagents used in the study (including **4** and **6a-6b**) were of commercial quality and were used as purchased. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were acquired using a BRUKER AVANCE® III HD 400 Spectrometer in CDCl<sub>3</sub> solutions at room temperature. Chemical shifts were given in chemical shift ( $\delta$ ) as parts per million (ppm) relative to tetramethylsilane (TMS). <sup>13</sup>C NMR spectra were determined at 100 MHz on a JEOL® 400YH Spectrometer in DMSO-d<sub>6</sub> with chemical shift ( $\delta$ ) given in parts per million (ppm) relative to TMS as internal standard and recorded at room temperature. The ESI-MS spectra were determined on a Waters Quattro Micro® Quadrupole Mass Spectrometer or on a Shimadzu® LCMS-2010 Quadrupole Mass Spectrometer. Thin layer

chromatography was performed on glass plates coated with 60 GF<sub>254</sub> silica. Plates were visualized using UV light (254 nm). We undertook the flash column chromatography *via* an Interchim Puriflash® 4100 medium pressure preparative chromatography apparatus with silica gel (Bonna-Agela® flash silica, 40–60  $\mu$ m, 60  $\text{\AA}$ ).

Truncated human FAK(PTK2) [376-1052(end) amino acids of accession number NP\_722560.1] was provided by Carna Biosciences, Inc. HTRF KinEASE®-TK kit was purchased from Cisbio Biosciences, Inc.

No-carrier-added (n.c.a.) <sup>18</sup>F<sup>-</sup> was generated by the bombardment of an enriched [<sup>18</sup>O]water target (>97%) with a proton beam using an the Sumitomo HM-20 cyclotron at Cancer Hospital of Peking University (Beijing, China). QMA light ion-exchange cartridges and C-18 light Sep-Pak® cartridges were obtained from Waters (Milford, MA). We activated the Waters Sep-Pak® Accell™ Plus QMA Plus Light Cartridges (130 mg Sorbent per Cartridge, 37–55  $\mu$ m particle size) with 1 N NaHCO<sub>3</sub> (10 mL), followed by deionized water (10 mL), and the Waters Sep-Pak® C18 Plus Light Cartridges (130 mg Sorbent per Cartridge, 55–105  $\mu$ m particle size) with methanol (10 mL) and deionized water (10 mL) before use. Radiopharmaceuticals were purified and their radiochemical purity were determined on a Shimadzu® LC-20AT HPLC apparatus equipped with a SPD-20A UV detector ( $\lambda$  = 254 nm) and Bioscan® flow count 3200 NaI/PMT  $\gamma$ -radiation scintillation detector. We performed the radiopharmaceutical HPLC separations on a Inertsil® ODS-3 C18 reverse phase semi-preparative column (GL Sciences, Inc. 5  $\mu$ m, 10 mm  $\times$  250 mm), and we carried out the elution with a binary gradient system at a flow rate of 2.0 mL min<sup>-1</sup>. Their radiochemical purity determination were achieved on a Kromasil® 100-5C18 reverse phase column (AkzoNobel, 5  $\mu$ m, 4.6 mm  $\times$  250 mm), and elution was with a binary gradient system at a flow rate of 2.0 mL min<sup>-1</sup>.

We purchased S180 ascites sarcoma mice from Beijing Vitalriver Animal Technology Co., Ltd., and Beijing Xinglong Animal Technology Co., Ltd. provided normal ICR mice (20–25 g, female). The measurement of the F-18 radioactivity of the tissues and organs of interest was performed on a PerkinElmer® 2480 WIZARD<sup>2</sup> automatic  $\gamma$ -counter. The Micro-PET imaging was performed on a Siemens Inveon DPET 120. All protocols requiring the use of mice were approved by the Animal Care Committee of Beijing Normal University.

### 2.2. Synthesis

#### 2.2.1. 5-Bromo-2-chloro-*N*-(4-methoxyphenyl)pyrimidin-4-amine (**5**).

The 4-methoxyphenyl amine **4** (150 mmol) was added to a solution of the 5-bromo-2,4-dichloropyrimidine **3** (100 mmol) in i-PrOH (200 mL) at ambient temperature. The first batch of precipitant appeared after a few minutes of stirring at r.t. After filtration, to the filtrate was added the solution of K<sub>2</sub>CO<sub>3</sub> (300 mmol) in water (200 mL), and the reaction mixture was stirred at room temperature until all of the 5-bromo-2,4-dichloropyrimidine **3** was consumed completely by TLC monitoring. The resulting second batch of precipitant was filtered and the filter cake was washed with



water and ethyl acetate in sequence. After desiccation, the two batches of precipitant were combined to gain the 5-bromo-2-chloro-*N*-phenylpyrimidin-4-amines **5** as a gray solid (16.17 g, 51.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  $\delta$  ppm): 8.25 (s, 1H), 7.47 (d,  $J$  = 9.0 Hz, 2H), 7.16 (brs, 1H), 6.93 (d,  $J$  = 9.0 Hz, 2H), 3.83 (s, 3H); ESI-MS: calcd for C<sub>11</sub>H<sub>9</sub>BrClN<sub>3</sub>O ([M + H]<sup>+</sup>) 314.0, found 314.0 ([M + H]<sup>+</sup>).

**2.2.2. 2-(2-(4-((5-Bromo-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (7a).** To the solution of **5** (1.38 g, 4.38 mmol) in 1,4-dioxane (15 mL) was added a mixture of **6a** (2.31 g, 6.57 mmol, 1.5 equiv.) and *p*-toluenesulfonic acid (PTSA, 0.30 g, 1.75 mmol, 0.4 equiv.), and the mixture was stirred at 100 °C for 4 h. After completion of the reaction monitored by TLC, the reaction mixture was quenched with saturated aqueous solution of sodium bicarbonate, extracted with ethyl acetate. After dried with sodium sulfate and filtration, the extract was concentrated *in vacuo*. The residue was purified by column chromatography (petroleum ether/AcOEt, 2/1 to 1/1) to give **7a** as a light yellow solid (0.48 g, 12.6%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  $\delta$  ppm): 7.94 (s, 1H), 7.81 (d,  $J$  = 8.3 Hz, 4H), 7.27–7.38 (m, 8H), 4.36 (t,  $J$  = 4.7 Hz, 2H), 4.15 (t,  $J$  = 4.6 Hz, 2H), 4.05 (t,  $J$  = 4.2 Hz, 1H), 3.96 (t,  $J$  = 4.7 Hz, 1H), 3.85 (s, 3H), 3.76 (t,  $J$  = 4.2 Hz, 1H), 3.66 (t,  $J$  = 5.2 Hz, 1H), 2.42 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>,  $\delta$  ppm): 158.73, 157.89, 157.24, 153.75, 152.99, 145.38, 135.07, 134.67, 134.21, 132.93, 130.60, 128.12, 122.24, 121.30, 116.70, 114.61, 92.72, 70.47, 69.46, 68.53, 67.67, 55.61, 21.57; ESI-MS: calcd for C<sub>28</sub>H<sub>29</sub>BrN<sub>4</sub>O<sub>6</sub>S ([M + H]<sup>+</sup>) 629.1, found 629.1 ([M + H]<sup>+</sup>).

**2.2.3. 2-(2-(4-((5-Bromo-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (7b).** The same reaction as described above to prepare **7a** was used, and **7b** was obtained as a light yellow solid (0.35 g, 15.8%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  $\delta$  ppm): 7.91 (s, 1H), 7.75 (d,  $J$  = 7.7 Hz, 1H), 7.68 (d,  $J$  = 7.5 Hz, 1H), 7.23–7.33 (m, 6H), 6.83 (d,  $J$  = 8.4 Hz, 2H), 6.73 (d,  $J$  = 7.8 Hz, 2H), 4.07 (t,  $J$  = 4.2 Hz, 2H), 3.80 (s, 3H), 3.62–3.71 (m, 10H), 2.38 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>,  $\delta$  ppm): 158.30, 157.89, 157.24, 153.92, 152.97, 145.23, 135.30, 134.62, 134.31, 132.89, 130.69, 128.11, 123.37, 121.27, 116.00, 114.69, 92.67, 70.89, 70.73, 70.45, 70.01, 68.72, 67.04, 55.67, 21.58; ESI-MS: calcd for C<sub>30</sub>H<sub>33</sub>BrN<sub>4</sub>O<sub>7</sub>S ([M + H]<sup>+</sup>) 673.1, found 673.0 ([M + H]<sup>+</sup>).

**2.2.4. 5-Bromo-*N*<sup>2</sup>-(4-(2-(2-fluoroethoxy)ethoxy)phenyl)-*N*<sup>4</sup>-(4-methoxyphenyl)pyrimidine-2,4-diamine ([<sup>19</sup>F]2).** A mixture of KF (10 mg, 0.17 mmol, 5.0 equiv.) and Kryptofix 2.2.2 (26 mg, 0.07 mmol, 2.0 equiv.) was added to a solution of **7a** (19 mg, 0.03 mmol) in anhydrous acetonitrile and the mixture was stirred in the digestion high-pressure tank at 100 °C for 15 min. Then the reaction mixture was quenched with water and extracted with ethyl acetate. After dried with sodium sulfate and filtration, the extract was concentrated *in vacuo*. The residue was purified by flash column chromatography (petroleum ether/AcOEt, 1/1) to give [<sup>19</sup>F]2 as a light yellow solid (14 mg, 97.2%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  $\delta$  ppm): 8.12 (s, 1H), 7.44 (d,  $J$  = 8.9 Hz, 2H), 7.37 (d,  $J$  = 8.9 Hz, 2H), 6.89 (d,  $J$  = 9.0 Hz, 2H), 6.84 (d,  $J$  = 8.9 Hz, 2H), 4.67 (t,  $J$  = 4.1 Hz, 1H), 4.55 (t,  $J$  = 4.1 Hz, 1H), 4.13 (t,  $J$  = 7.2 Hz, 2H), 3.89 (t,  $J$  = 5.0 Hz, 2H), 3.84 (s, 3H), 3.80 (t,  $J$  = 4.2 Hz, 1H), 3.66 (t,  $J$  = 4.0 Hz, 1H);

<sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>,  $\delta$  ppm): 158.76, 157.93, 157.23, 153.80, 152.99, 135.07, 134.67, 134.21, 122.24, 121.32, 116.70, 114.63, 102.10, 92.70, 84.39, 82.74, 70.41, 70.22, 69.58, 67.78, 55.60; <sup>19</sup>F NMR (CDCl<sub>3</sub>,  $\delta$  ppm): -223.28 (1F); ESI-MS: calcd for C<sub>21</sub>H<sub>22</sub>BrFN<sub>4</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 477.1, found 477.1 ([M + H]<sup>+</sup>).

**2.2.5. 5-Bromo-*N*<sup>2</sup>-(4-(2-(2-fluoroethoxy)ethoxy)ethoxy)phenyl-*N*<sup>4</sup>-(4-methoxyphenyl)pyrimidine-2,4-diamine ([<sup>19</sup>F]3).** The same reaction as described above to prepare [<sup>19</sup>F]2 was used, and [<sup>19</sup>F]3 was obtained as a light yellow solid (15 mg, 93.7%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  $\delta$  ppm): 7.91 (s, 1H), 7.44 (d,  $J$  = 8.9 Hz, 2H), 7.36 (d,  $J$  = 5.0 Hz, 2H), 6.91 (d,  $J$  = 8.4 Hz, 2H), 6.80 (d,  $J$  = 8.2 Hz, 2H), 4.67 (t,  $J$  = 4.1 Hz, 1H), 4.54 (t,  $J$  = 4.1 Hz, 1H), 4.12 (t,  $J$  = 7.2 Hz, 2H), 3.84 (t,  $J$  = 5.0 Hz, 2H), 3.84 (s, 3H), 3.64–3.73 (m, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>,  $\delta$  ppm): 158.79, 157.93, 157.27, 153.87, 152.97, 135.06, 134.67, 134.32, 122.27, 121.32, 116.02, 114.67, 102.11, 92.71, 84.67, 82.97, 71.08, 70.63, 70.44, 70.31, 69.61, 67.03, 55.63; <sup>19</sup>F NMR (CDCl<sub>3</sub>,  $\delta$  ppm): -222.97 (1F); ESI-MS: calcd for C<sub>23</sub>H<sub>26</sub>BrFN<sub>4</sub>O<sub>4</sub> ([M + H]<sup>+</sup>) 521.1, found 521.0 ([M + H]<sup>+</sup>).

### 2.3. Radiochemistry

[<sup>18</sup>F]2 and [<sup>18</sup>F]3 were radiosynthesized and isolated as the procedure described in the literature:<sup>22</sup> first, [<sup>18</sup>F]fluoride was transferred to a hot cell, passed through and trapped on a preconditioned anion exchange cartridge (QMA cartridge, preconditioned as those described in Section 2.1). The fixed <sup>18</sup>F<sup>-</sup> was eluted from the QMA cartridge to a digestion high-pressure tank with a solution of 1.5 mL of (Kryptofix 2.2.2)/K<sub>2</sub>CO<sub>3</sub> solution (a mixture of 13.5 mg of Kryptofix 2.2.2 in 1.25 mL CH<sub>3</sub>CN and 1.7 mg K<sub>2</sub>CO<sub>3</sub> in 0.25 mL H<sub>2</sub>O). The solvents were removed under a sweep stream of nitrogen at 100 °C. Subsequently, 0.5 mL of dry CH<sub>3</sub>CN was added to the residue and evaporated to dryness for three times. Then, to the resulted dry Kryptofix 2.2.2/[<sup>18</sup>F] KF complex, a solution of the tosylate precursors **7a** and **7b** in dry CH<sub>3</sub>CN (0.5 mL) was added, respectively, and the mixture was stirred at 100 °C for 15 min and diluted with deionized H<sub>2</sub>O (10 mL) and loaded onto an activated C18 Sep-Pak cartridge (pretreated as those described in Section 2.1). The Sep-Pak cartridge was washed with deionized H<sub>2</sub>O (10 mL) again to remove unlabeled <sup>18</sup>F<sup>-</sup> and the organic phase was then eluted with 2 mL of CH<sub>3</sub>CN for two times. The combined eluent was concentrated *in vacuo*, and the residue in 0.4 mL of CH<sub>3</sub>CN was injected into a semi-preparative HPLC. The preparation took 60 min, and the [<sup>18</sup>F]2 and [<sup>18</sup>F]3 were separated in a radiochemical yield of 9–16% (decay not corrected), respectively. The radiochemical purity of all tracers was greater than 98%.

### 2.4. Octanol/water partition coefficient

The radioactivity of the *n*-octanol layer and that of the PBS layer for [<sup>18</sup>F]2 and [<sup>18</sup>F]3 were measured as previously described in our recent work:<sup>22</sup> we added a 0.1 mL solution of each of the radiotracers (370 KBq, 10 µCi) in normal saline to a tube containing 0.9 mL of phosphate-buffered saline (0.05 M, PBS, pH 7.4) and 1.0 mL of *n*-octanol (each phase had been presaturated with the opposite phase overnight before use). The mixture was



vortexed for 0.5–1.0 min and centrifuged at 5000 rpm for 5 min. Aliquots of both phases were transferred in triplicate with micropipettes to counting tubes and were assayed in a  $\gamma$ -counter after standing for a while. Then, the partition coefficient was calculated by dividing the radioactivity of the *n*-octanol layer with that of the PBS layer. This measurement was repeated three times.

## 2.5. Stability test *in vitro*

The stability test *in vitro* of the radiotracers were performed following the procedure in our previous report:<sup>22</sup> each of the radiotracers (370 kBq, 10  $\mu$ Ci) purified by the HPLC in 100  $\mu$ L of normal saline was mixed with 500  $\mu$ L of normal saline at 37 °C for 1 h and 2 h, respectively. Approximately 0.1 mL of the solution was analyzed by radio-HPLC (about the HPLC analysis condition, please refer to the above Section 2.1).

The stability of each HPLC-purified radiotracer in mouse plasma was determined by incubating 100  $\mu$ L of radiotracer (370 kBq, 10  $\mu$ Ci) in the solution of 500  $\mu$ L murine plasma at 37 °C for 1 h and 2 h, respectively. Plasma proteins were precipitated by adding 200  $\mu$ L of acetonitrile after centrifugation at 5000 rpm for 5 min at 4 °C. About 100  $\mu$ L of the supernatant part was injected into radio-HPLC.

## 2.6. Bioactivity

**2.6.1. Inhibition test of the compounds against FAK and biochemical assay for kinase selectivity profiling.** In this work, we carried out the FAK inhibitory assays of the F-19 standards [<sup>19</sup>F]2 and [<sup>19</sup>F]3, and the profiling of the [<sup>19</sup>F]2 against five kinds of kinases (PYK2, JAK2, IGF-1R, EGFR and PDGFR $\beta$ ) with the HTRF® (Homogeneous Time-Resolved Fluorescence Methodologies) kinEASE™-TK kit, strictly according to the methods in the Section 4.6 of our published work:<sup>22</sup>

We carried out the FAK inhibitory assays of the F-19 standards [<sup>19</sup>F]2 and [<sup>19</sup>F]3, and the profiling of the [<sup>19</sup>F]2 against five kinds of kinases (PYK2, JAK2, IGF-1R, EGFR and PDGFR $\beta$ ) with the HTRF® (Homogeneous Time-Resolved Fluorescence Methodologies) kinEASE™-TK kit.

Before the compound testing, the optimization of the concentration of the enzyme used in the assay, as well as the enzymatic reaction time and the ATP concentration was performed.

Phosphorylation of the TK substrate-biotin was challenged with serially diluted compounds at 1/2-log concentrations starting at a top concentration of 100  $\mu$ M (which was the final concentration for the enzymatic step (10  $\mu$ L)). Each concentration was tested in triplicate.

During enzymatic reaction step, 4  $\mu$ L compounds in kinase buffer and 2  $\mu$ L TK substrate-biotin were incubated with 2  $\mu$ L kinase in kinase buffer and 2  $\mu$ L ATP in kinase buffer (with the above optimized concentration) was added to start the enzymatic reaction. The mixture was incubated for the above optimized time at room temperature.

The detection reagents [5  $\mu$ L Eu<sup>3+</sup>-cryptate labeled TK antibody in HTRF® detection buffer, and 5  $\mu$ L streptavidin-XL665 in HTRF® detection buffer (0.125  $\mu$ M, which was the

final concentration for the assay (20  $\mu$ L)] were mixed and added to the reaction system. The TR-FRET signal was proportional to the phosphorylation level and was detected by a plate reader (BMG FS) after being incubated for one hour. For each compound, the determination of the IC<sub>50</sub> value was from a sigmoid dose-response curve using Graph-Pad Prism (GraphPad Software, San Diego, CA, USA).

## 2.6.2. Building of the S180 tumor bearing mice model and the identification of the expression level of FAK in S180 tumor.

First, the animal model of the S180 tumor bearing mice was built following the procedure in the literature:<sup>22</sup> the S180 sarcoma cell suspension was made of the ascites transferred from a sacrificed S180 ascites sarcoma mouse, and was diluted four times by the normal saline before use. Next, we inoculated the normal ICR mice subcutaneously into the right front flank with the diluted ascites sarcoma cell suspension (0.1 mL per mouse, containing approximately  $5 \times 10^6$  tumor cells by cell count). It would take about one week for the tumors to reach a size of 0.5–0.8 cm in diameter before the *in vivo* biodistribution studies could be conducted.

Then, sixty pieces of tumor tissue slices (about 4  $\mu$ m) from sixty S180 tumor bearing mice, and sixty pieces of normal muscle tissue slices (about 4  $\mu$ m) from sixty normal mice, were used for immunohistochemistry for the identification of the expression level of FAK in S180 tumor.

For the immunohistochemistry, the working concentration of the FAK monoclonal antibody (purchased from Santa Cruz Biotechnology Co., LTd.) was 1 : 40, and the working concentration of the phospho-FAK (pY397FAK) polyclonal antibody (purchased from Upstate Bio technology Co., LTd.) was 1 : 800.

The ready-to-use UltraSensitive™ SP kit (SP9000), the sensitizer DAB (diaminobenzidine) and the HE (hematoxylin-eosin) staining kit were purchased from Beijing Zhongshan company.

All the tumor tissue slices and normal muscle tissue slices were carried out for HE staining and immunohistochemical staining, with PBS instead of the FAK monoclonal antibody and the pY397FAK polyclonal antibody as the negative control. And the detailed procedures of the immunohistochemistry were according to the SP kit instructions.

The criteria of immunohistochemical results could be divided into four kinds of levels according to the rate of the FAK-positive/pY397FAK-positive cell and the intensity of the staining reaction of the tissue splices: (1) “negative (–)” means that the cell of the tissue slices were not stained, or the rate of the FAK-positive/pY397FAK-positive cell was lower than 25%; (2) “weak positive (+)” means that the cell of the tissue slices were stained as brown yellow, or the rate of the FAK-positive/pY397FAK-positive cell was between 25% and 50%; (3) “moderate positive (++)” means that the cell of the tissue slices were stained as pale yellow, or the rate of the FAK-positive/pY397FAK-positive cell was between 51% and 75%; (4) “strong positive (++)” means that the cell of the tissue slices were stained as brown, or the rate of the FAK-positive/pY397FAK-positive cell was higher than 75%.

**2.6.3. *In vivo* studies in mice bearing S180 tumor.** The *in vivo* biodistribution study & micro-PET imaging study &



blocking study were carried out following the procedure in the literature.<sup>22</sup>

Each of the S180 tumor bearing mice was injected *via* the tail vein with a normal saline solution containing the <sup>18</sup>F-labeled tracers (370 kBq per 100  $\mu$ L). At 5, 15, 30, 60 and 120 min post injection, five mice for each time point were sacrificed by decapitation. The tissues and organs of interest were immediately collected, weighed and measured for <sup>18</sup>F radioactivity in an automatic gamma counter. The percent dose per gram of wet tissue was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. The values were expressed as mean  $\pm$  SD ( $n = 5$ ).

For Micro-PET imaging study, the S180 tumor bearing mouse was injected intravenously with approximately 3.7 MBq of [<sup>18</sup>F]2 in 300  $\mu$ L normal saline, anesthetized with 1.5% isoflurane in air (about 1.5 mL min<sup>-1</sup>) and fixed near the center of Micro-PET scanner with prone position. Static scans (for 30 min, 10 min scan) were obtained on a Siemens Inveon DPET 120. Then, the images were reconstructed and the images were exported.

For blocking studies in the *in vivo* biodistribution and micro-PET imaging studies, at one hour prior to the injection of the radiotracer [<sup>18</sup>F]1, a group of mice received PF-562271 in 5% Gelucire 44/14 in sterile water (Gattefosse) (dose: 33 mg kg<sup>-1</sup>, p.o.).

## 2.7. Computational chemistry

The structure of the NVP-TAE226 (the chemical structure of it was shown in the Section 2.5 of our previous report<sup>22</sup>), which was in the complex with FAK (the RCSB Protein Data Bank (PDB) deposition number of the X-ray single-crystal diffraction structures: 2JKK), was selected as the molecular template for sketching the structures of the F-19 standards in this work. For each of the compounds, the conformations resulting from molecular docking, were obtained *via* the previous structure sketching, molecular energy minimization, systematic conformational search using the Sybyl-X 1.3 molecular modeling software package (Tripos Associates, St. Louis, MO), AM1 optimization on Gaussian 09 and the molecular docking into the ATP binding site of FAK based on 2JKK.pdb with AutoDock 4.0. The results of the docking studies were viewed with the Sybyl-X 1.3.

The conformations resulting from molecular docking were served as the initial conformations of ligands for the MD simulations, and the subsequent MD simulations were also undertaken following the protocols in the Section 4.8 of the literature.<sup>22</sup>

## 3. Results and discussion

### 3.1. Organic synthesis

Scheme 1 offers an overview of the synthetic route of the tosylate precursors **7a–7b** and the fluoro-pegylated 5-bromopyrimidine derivatives [<sup>19</sup>F]2–[<sup>19</sup>F]3. The 5-bromo-2-chloro-N-(4-methoxyphenyl)pyrimidin-4-amine **5** was prepared by the stirring of the starting material 5-bromo-2,4-dichloropyrimidine 3

reacted with the 4-methoxyphenyl amine **4** under K<sub>2</sub>CO<sub>3</sub> at room temperature. Subsequent treatment of the compound **5** with the different substituted aryl amines **6a–6b** above in presence of *p*-toluenesulfonic acid (PTSA) yielded the desired tosylate precursors **7a–7b**. Preparation of the F-19 standards [<sup>19</sup>F]2–[<sup>19</sup>F]3 of the corresponding radiotracers [<sup>18</sup>F]2–[<sup>18</sup>F]3 in this study was accomplished by the fluorination of the tosylate precursors **7a–7b** with anhydrous KF and Kryptofix 2.2.2 in dry acetonitrile at 100 °C for just 15 min.

### 3.2. Radiochemistry

The desired F-18 labeled tracers [<sup>18</sup>F]2 and [<sup>18</sup>F]3 were synthesized by the nucleophilic substitution of the tosylate precursors **7a** and **7b** under conventional conditions (<sup>18</sup>F)fluoride/potassium carbonate and Kryptofix 2.2.2) in anhydrous acetonitrile at using a digestion high-pressure tank at 100 °C for 15 min, respectively (Scheme 1), affording [<sup>18</sup>F]2 and [<sup>18</sup>F]3 in 16% and 12% radiochemical yield (non-decay-corrected), respectively, and radiochemical purity of greater than 98% after solid phase extraction and HPLC purification. The total synthesis time was 60 min. The identity of the [<sup>18</sup>F]2 and [<sup>18</sup>F]3 was further confirmed by comparing theirs HPLC retention time with those of co-injected authentic nonradioactive F-19 standards [<sup>18</sup>F]2 and [<sup>18</sup>F]3 (Fig. 1), respectively, using analytical HPLC conditions described in the Section 2.1. Specific activity, estimated by comparing the UV peak intensity of purified F-18 labeled compounds with reference nonradioactive compounds, ranged from 34 to 52 GBq  $\mu$ mol<sup>-1</sup> at the end of synthesis.


### 3.3. *In vitro* stability study

It could be seen from the radio-HPLC analysis that all the radiotracers were stable in both normal saline and murine plasma at 37 °C after 1 h and 2 h (Fig. S1) (see the ESI†). We chose two solvent conditions – normal saline and murine plasma in the *in vitro* stability study for the following reasons: first, since the radiotracers were injected into the body as a normal saline solution, their stability in normal saline should be observed. What's more, their *in vitro* stability in murine plasma should also be determined, because we often use mice as the primary animal model to carry out the *in vivo* biological evaluation. Therefore, if the radiotracers were not stable even in the murine plasma, they would be unstable after being injected into the blood of the mice and won't effectively reach the target organ. So the following biological evaluation would be meaningless.

### 3.4. Bioactivity

**3.4.1. *In vitro* inhibition test of the compounds [<sup>19</sup>F]1, [<sup>19</sup>F]2 and [<sup>19</sup>F]3 against FAK, and kinase selectivity profile of the F-19 standard [<sup>19</sup>F]2.** Using an kinase assay based on HTRF described in the Section 2.6.1, we carried out *in vitro* evaluation for their ability to inhibit FAK kinase activity for all of the F-19 standards. We used PF-562271 (one reported inhibitor of FAK, developed by Pfizer Inc.) as positive control drug to prove the rationality of the FAK inhibitory assay conditions. Similar to





**Scheme 1** Reagents and conditions: (a)  $\text{K}_2\text{CO}_3$ ,  $\text{iPrOH} : \text{H}_2\text{O} = 1 : 1$  (v/v), r.t.; (b) PTSA ( $p$ -toluenesulfonic acid), 1,4-dioxane, reflux; (c) anhydrous KF, Kryptofix 2.2.2, anhydrous acetonitrile,  $100^\circ\text{C}$ ; (d)  $^{18}\text{F}^-$ ,  $\text{K}_2\text{CO}_3$ , Kryptofix 2.2.2, anhydrous acetonitrile,  $100^\circ\text{C}$ .

previously reported data (1.5 nM),<sup>11</sup> PF-562271 inhibited the activity of FAK with  $\text{IC}_{50}$  value of 4.3 nM (Table 1) under the experimental conditions.

Although it was similar to the results in our published work<sup>22</sup> that the interaction between the F-19 standards ( $[^{19}\text{F}]1$ ,  $[^{19}\text{F}]2$  and  $[^{19}\text{F}]3$ ) and the FAK was also mainly affected by the length of the FPEG chain, there were some improvement in this study, comparing to our previous reports.<sup>22,23</sup> (1) the FAK inhibitory potency improved by 19.0-fold when the FPEG chain on the F-19 standards was lengthened from  $n = 1$  in our published work<sup>23</sup> to  $n = 2$  in this study; (2) the result of the  $[^{19}\text{F}]2$  were relatively good and had a modest  $\text{IC}_{50}$  of 57.1 nM, which were even better than the relatively good result (91.4 nM) in our published work.<sup>22</sup> However, when we continued to lengthen the FPEG chain from  $n = 2$  to  $n = 3$ , it also led to an dramatic 19.5-fold reduction of interaction between the F-19 standards and the FAK again.

The relatively best F-19 standard  $[^{19}\text{F}]2$  were also further profiled *in vitro* against other five kinds of cancer-related kinases (PYK2, JAK2, IGF-1R, EGFR and PDGFR $\beta$ ), also using an HTRF® based kinase assay described in the Section 2.6.1, and with NVP-TAE226 (ref. 32) (one reported inhibitor of FAK developed by Novartis International AG) as the positive control substance.

We could observed from the Table 2 that the  $[^{19}\text{F}]2$  displayed an good selectivity profile against the tested kinases, with 62.4 folds selectivity against PYK2, 75.5 folds selectivity against EGFR, and more than 200 folds selectivity against IGF-1R and PDGFR $\beta$ , which were also even better than the results in our published work.<sup>22</sup>

**3.4.2. The identification of the expression level of FAK in S180 tumor.** FAK-positive/pY397FAK-positive substances were stained in the cytoplasm of most S180 sarcoma cells in the tumor tissue slices (Fig. 2), while most of the normal muscle




Fig. 1 The HPLC chromatogram of F-18 labeled radiotracers and the corresponding F-19 standards. The HPLC profile data were exported from the \*.lcd files by Shimadzu LCSolution Software and were graphically interpreted and coordinate translated by Origin 8.0.

Table 1 *In vitro* enzymatic IC<sub>50</sub> against FAK for F-19 standards [<sup>19</sup>F]1<sup>a</sup>, [<sup>19</sup>F]2 and [<sup>19</sup>F]3 against FAK in comparison with PF-562271

Compounds	IC <sub>50</sub> ± SD <sup>b</sup> (nM)
[ <sup>19</sup> F]1	1085.4 ± 47.2
[ <sup>19</sup> F]2	57.1 ± 8.3
[ <sup>19</sup> F]3	1113.6 ± 60.9
PF-562271	4.3 ± 0.3

<sup>a</sup> The preparation and the related biological evaluation results of [<sup>19</sup>F]1 and its corresponding F-18 labeled radiotracer [<sup>18</sup>F]1, have been described in our published work.<sup>23</sup> (Note: the [<sup>19</sup>F]1 in this work was named **8a** in our published work.<sup>23</sup> The chemical structure of [<sup>19</sup>F]1 was shown in the ESI.) The *in vitro* inhibition test of [<sup>19</sup>F]1 against FAK, were performed in the same batch with the F-19 standards in this work. <sup>b</sup> Mean of three determinations.

cells are not stained or just weakly stained. The moderate and strong positive expression rates of FAK and pY397FAK in sixty S180 tumor tissues (58.3% and 40.0% respectively) were significantly higher than those in sixty normal muscle tissues (11.7% and 6.7% respectively), with statistical significance ( $P < 0.05$ ) (Table 3). This suggested that the FAK was highly expressed or over-expressed in S180 tumor tissue.

**3.4.3. *In vivo* biodistribution studies in S180-tumor-bearing mice.** It could be concluded from Tables S1-S3 (see the ESI†) that as following:

(1) The uptake of all of the three F-18 labeled compounds in tumor, accumulated to their respective high levels at 15 min post-injection ( $3.69 \pm 0.51$ ,  $5.40 \pm 0.12$  and  $2.80 \pm 0.33$  % ID per g for [<sup>18</sup>F]1, [<sup>18</sup>F]2 and [<sup>18</sup>F]3, respectively), and remained at analogously high levels at 30 min post-injection ( $3.71 \pm 0.43$ ,  $5.96 \pm 0.09$  and  $3.24 \pm 0.07$  % ID per g for [<sup>18</sup>F]1, [<sup>18</sup>F]2 and [<sup>18</sup>F]3, respectively). They reached to their peak value at 30 min post-injection ( $3.71 \pm 0.43$ ,  $5.96 \pm 0.09$  and  $3.24 \pm 0.07$  % ID per g for [<sup>18</sup>F]1, [<sup>18</sup>F]2 and [<sup>18</sup>F]3, respectively). After that, the value started to decline at 60 min post-injection and 120 min post-injection. However, for all the three tracers, their retention in tumor was relatively long, because the radioactivity was still more than half of the peak value at 120 minutes post-injection ( $3.11 \pm 0.22$ ,  $3.86 \pm 0.14$  and  $2.88 \pm 0.44$  % ID per g for [<sup>18</sup>F]1, [<sup>18</sup>F]2 and [<sup>18</sup>F]3, respectively). The statement of “relatively long retention in tumor” here was just referred to the page 3782 in one of the reports of the Qi’s group<sup>33</sup>). And all the three radiotracers showed moderate clearance from blood and metabolism in kidney, which were conclude from the uptake of the three radiotracers in the blood and kidney from 5 min post-injection to 120 min post-injection.

(2) Not only did the length of the FPEG chain has a significant effect on the interaction between the F-19 standards in this work ([<sup>18</sup>F]1-[<sup>18</sup>F]3) (expressed as the *in vitro* inhibitory abilities of enzymatic activities of FAK in this article) and the FAK at the molecular level, but also it played a vital role in the

Table 2 *In vitro* profile of [<sup>19</sup>F]2 against five kinds of cancer-related kinases compared to NVP-TAE226

Kinase	IC <sub>50</sub> ± SD (nM) for [ <sup>19</sup> F]2 <sup>a</sup>	IC <sub>50</sub> ± SD (nM) for NVP-TAE226 <sup>a</sup>	Reported IC <sub>50</sub> (nM) for NVP-TAE226 (ref. 32)
PYK2	3560.8 ± 625.6	5.7 ± 1.4	3.5 ± 2.1
JAK2	11 720.0 ± 1981.3	868.9 ± 152.6	840 ± not shown
IGF-1R	16 600.3 ± 2957.1	182.4 ± 40.1	140 ± 28.3
EGFR	4311.4 ± 562.1	1829.1 ± 466.2	1700 ± not shown
PDGFR $\beta$	32 850.2 ± 4513.7	2321.0 ± 574.4	2600 ± 1600

<sup>a</sup> Mean of three determinations.






Fig. 2 An example of strong positive FAK and pY397FAK staining in S180 tumor tissue slices (SP  $\times 200$ ).

biodistribution of the corresponding F-18 labeled radiotracers ( $[^{18}\text{F}]1-[^{18}\text{F}]3$ ) in the S180-tumor-bearing mice models at the organ level. The uptake of the radiotracers in tumor improved from  $[^{18}\text{F}]1$  to  $[^{18}\text{F}]2$ , with the addition of the FPEG chain from  $n = 1$  to  $n = 2$ , which was mainly because, the enhanced FAK inhibitory activity of the F-19 standards reflected the increased interaction between the F-19 standards and the FAK, when the FPEG chain lengthened from  $n = 1$  to  $n = 2$ . However, when the FPEG chain continued to lengthen, the interaction between the F-19 standards and the FAK was incredibly weakened, leading to the dramatical reduction of the uptake of  $[^{18}\text{F}]3$  in tumor and some of its target/non-target ratio (tumor/bone, tumor/muscle and tumor/blood ratio, *e.g.*) (even lower than those of  $[^{18}\text{F}]1$ ). Therefore, the stronger the interaction between the F-19 standards and the FAK, the higher the uptake of the corresponding F-18 labeled tracers in tumor in this work. And another reason for the relative highest uptake of  $[^{18}\text{F}]2$  at 30 min post-injection among the  $[^{18}\text{F}]1-[^{18}\text{F}]3$ . And another possible reason for the relative highest uptake of  $[^{18}\text{F}]2$  at 30 min post-injection among the  $[^{18}\text{F}]1-[^{18}\text{F}]3$  is that, the  $[^{18}\text{F}]2$  showed faster clearance from the lung (one of the non-target organs) than those for  $[^{18}\text{F}]1$  and  $[^{18}\text{F}]3$ , which was conclude from the uptake of the three radiotracers in the lung from 5 min post-injection to 30 min post-injection.

(3) For the  $[^{18}\text{F}]2$ , we could observe distinct reduced uptake (about 88%) of the radiotracer in the tumor tissue ( $0.72 \pm 0.05$  % ID per g at 30 min post-injection of  $[^{18}\text{F}]2$ ) in mice that received PF-562271 (one of the reported best selective FAK inhibitor which was developed by Pfizer Inc.) at one hour before the injection of radiotracer.

From the above analysis, it could be obtained that in order to further increase the uptake of the F-18 labeled tracer in tumor, the following properties of compounds should be improved: (1) the F-18 labeled tumor radiotracers which have closer interaction with the FAK (namely the stronger FAK inhibitory activity) should be further designed in the future. For example, we should build 3D-QSAR models with the experimental FAK  $\text{IC}_{50}$  data of the reported FAK inhibitors to make reasonable guidance for our drug design and quantitatively predict the FAK  $\text{IC}_{50}$  values of the molecular designed by us. What's more, some functional groups which have hydrogen-bonding or salt-bridge interactions with the key residues such as Asp564, Lys454 and Glu506 in the kinase domain of FAK, should be considered to improve the interaction of the drug molecules with the FAK; (2) in this work, the different speed of clearance from the lung affected the uptake of the radiotracers in tumor. This suggested that the F-18 radiotracers with better pharmacokinetic properties should be designed to improve uptake of the radiotracers in tumor and the speed of clearance from the non-target organs. Dynamic drug absorption and distribution model in different tissues (such as liver, blood, liver, tumor *etc.*) should be made. The general approach in pharmacokinetic and drug design studies, include calculation of many physical properties about pharmacokinetic properties (such as fat and water partition coefficient –  $\log P$ , dipole moment, apparent volume of distribution –  $V_d$ , time to peak –  $T_{\text{max}}$ , *etc.*) from the relevant data of the reported hundreds of small molecular tumor imaging agents, linear fitting of the physical properties to make the dynamic drug absorption and building of the distribution equation in different tissues. Then, we could use these equations to predict whether the molecules

Table 3 Expression of FAK and pY397FAK in sixty normal muscle tissue slices and sixty S180 tumor tissue slices

Group	FAK				Moderate and strong positive expression rates	pY397FAK				Moderate and strong positive expression rates
	–	+	++	+++		–	+	++	+++	
Normal muscle tissue slices ( $n = 60$ )	25	28	7	0	11.7%	47	9	4	0	6.7%
S180 tumor tissue slices ( $n = 60$ )	8	17	18	17	58.3%	25	11	15	9	40.0%



have ideal absorption in tumor and low uptake in non-target tissues, on the basis of the small molecules which have strong interaction with the FAK. These need to take a lot of work, and the relevant study is being carried out by our group.

**3.4.4. Micro-PET imaging studies of  $[^{18}\text{F}]2$  in S180-tumor-bearing mice.** The  $[^{18}\text{F}]2$ , which showed relatively good biodistribution results, was also chosen to carry out the small animal PET imaging studies in the mouse bearing S180 tumor. Coronal micro-PET images of a mouse bearing S180 tumor at 30 min after tail vein injection of  $[^{18}\text{F}]2$  were shown in Fig. 3A. In consistent with the above biodistribution results, relatively high tracer uptake in tumor (pointed to by the arrowhead) in the right front flank was observed at 30 min post-injection, while no accumulation in the left front flank was found. The imaging results clearly confirmed that  $[^{18}\text{F}]1$  could be accumulated in tumor at 30 min post-injection, which was better than the results of the imaging study in our previous report.<sup>23</sup> In addition, at 30 min post-injection, the activity in bladder, kidney and intestine, was also obvious, which was due to the metabolism in kidney and intestine (since the mice were fixed near the center of micro-PET scanner with prone position, but the mice were inoculated subcutaneously into the “right front flank” in the supine position with the diluted ascites sarcoma cell suspension. Therefore, we called the “left front flank” seen from the Fig. 3 as the “right front flank” from the supine position is this work).

What's more, Fig. 3B (blocking study) showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min

post-injection in mice that received PF-562271 (the positive control drug) at one hour before the injection of radiotracer. Therefore, the micro-PET imaging study, in combination with the results of the above kinase profiling assay and our biodistribution data, indicated that the uptake of  $[^{18}\text{F}]2$  in tumor of the mouse model was due to FAK over-expression or high expression in tumor, and that  $[^{18}\text{F}]2$  might be a kind of selectively FAK-targeted tumor imaging agents.

### 3.5. MD simulations and docking studies

In this section, the molecular dynamics (MD) simulations were applied to further understand the changing trends of the interaction between the different F-19 standards and the FAK, and the uptake of the corresponding F-18 labeled tracers in tumor theoretically, in view of the fact that the MD simulations were carried out with taking the solvent effect on the conformational transitions of the complexes (be comprised of ligands such as the F-19 standards in this work and receptors such as FAK in this study) into full consideration, while the simple docking analysis ignored both the flexibility of the proteins (receptors) and the effect of solvation in water.

First of all, the rationality of the MD simulations and the validity of the molecular conformation that was used as the initial conformation for the MD simulations, were proved, according to the Section 2.5 in our previous work.<sup>22</sup>

Then, we undertook the 40 ns MD simulations for all of the three F-19 standards in this work. It could be concluded from





Fig. 3 Coronal micro-PET images of mice bearing S180 tumor at 30 min post-injection of  $[^{18}\text{F}]2$  (A) and 30 min post-injection of  $[^{18}\text{F}]2$  after treatment of PF-562271 (a dose of  $33 \text{ mg kg}^{-1}$ , p.o.) at one hour before the intravenous injection of radiotracer (blocking study) (B).





**Fig. 4** The root-mean-square deviations (RMSD) between the starting conformations and the ones during the MD simulation as a function of the simulation time, for the complex (red) and the ligand (blue) in the complexes respectively, which were calculated with the *ptraj* module of Amber 10 and graphically interpreted by Origin 8.0. The MD simulation production phase was undertaken for 40 ns with a 2 ps time step, namely, 20 000 snapshots in sum. The calculating time for the MD simulation for each compound was about one month on the basis of our current computer cluster condition.

the Fig. 4 that, after equilibration, the RMSD values between the initial conformation and the one during the MD simulation for most of the complexes and ligands were less than 2.0 Å. In addition, the stronger the FAK inhibitory activity the F-19 standard had, the stronger the interaction between the F-19 standard and the FAK, the easier the complex system would enter into a state of equilibrium.

Table 4 lists the components of molecular mechanics and solvation energies. The mean value of electrostatic energy ( $\Delta E_{\text{electrostatic}} + \Delta \Delta G_{\text{PB}}$ ) was 27.3 kcal mol<sup>-1</sup> with a root-mean-square deviation of 1.6 kcal mol<sup>-1</sup>. For the van der Waals and hydrophobic interaction energies ( $\Delta E_{\text{vdW}} + \Delta \Delta G_{\text{SA}}$ ), the mean value was -56.5 with a root-mean-square deviation of 2.1 kcal mol<sup>-1</sup>. The entropy ( $T\Delta S$ ) had the a root-mean-square

**Table 4** Results of free energy calculation by MM-PBSA and NMODE module of Amber 10<sup>a</sup>, and the comparison between the calculated ( $\Delta G_{\text{bind,calc}}$ ) and the experimental binding free energies ( $\Delta G_{\text{bind,exp}}$ ) estimated from  $\text{IC}_{50}$ <sup>a</sup>

Complex	$\Delta E_{\text{electrostatic}}$	$\Delta E_{\text{vdW}}$	$\Delta E_{\text{gas}}$	$\Delta \Delta G_{\text{PB}}$	$\Delta \Delta G_{\text{SA}}$	$\Delta G_{\text{MMPSA}}$	$T\Delta S$	$\Delta G_{\text{bind,calc}}$	$\Delta G_{\text{bind,exp}}^b$
[ <sup>19</sup> F]1-FAK	-10.87	-46.48	-57.35	38.42	-8.93	-27.86	-20.13	-7.73	-8.17
[ <sup>19</sup> F]2-FAK	-13.12	-49.23	-62.35	41.86	-9.69	-30.18	-20.66	-9.52	-9.87
[ <sup>19</sup> F]3-FAK	-14.76	-44.47	-59.23	40.29	-10.74	-29.68	-22.09	-7.59	-8.15

<sup>a</sup> All energies are in kcal mol<sup>-1</sup>. <sup>b</sup> The  $\Delta G_{\text{bind,exp}}$  (experimental binding free energies) were estimated for the F-19 standards from the experimental  $\text{IC}_{50}$  values using the following relationship:  $\Delta G_{\text{bind,exp}} = RT \ln K_{\text{dissociated}} = RT \ln (\text{IC}_{50} + 0.5C_{\text{enzyme}}) \approx RT \ln \text{IC}_{50}$ , where  $R$  was ideal gas constant,  $T$  was the temperature in kelvin (298 K was used in this work), and  $C_{\text{enzyme}}$  was the concentration of enzyme, which was a very small number after equilibration and could be omitted in most cases.




Fig. 5 Comparison between the calculated and the experimental binding free energies estimated from  $IC_{50}$ .

deviation of  $1.0 \text{ kcal mol}^{-1}$  with a mean value of  $-21.0 \text{ kcal mol}^{-1}$ . The average unsigned error between the experimental and the calculated energy was  $0.45 \text{ kcal mol}^{-1}$  and the root-mean-square deviation was  $0.11 \text{ kcal mol}^{-1}$ . It could be seen from Fig. 5 that the calculated free energies reproduced the experimental ones relatively well and the rank order of calculated free energies and that of the experimental ones was generally consistent.

In addition, some conclusions obtained from the docking studies (Fig. S2) (see the ESI†), could also help us to understand why the small changes of chain length could bring a significant difference in  $IC_{50}$  values:

In the binding pocket of FAK, there were four intermolecular hydrogen bonds between  $[^{19}\text{F}]2$  and the kinase domain of FAK, which were formed by one N-atom on the pyrimidine ring of  $[^{19}\text{F}]2$  with one “-NH-” group on the residue Cys 502 of FAK, the “-NH-” group on the pyrimidine ring of  $[^{19}\text{F}]2$  with the one O-atom on the residue Cys 502 of FAK, the second O-atom on the FPEG chain of  $[^{19}\text{F}]2$  with the “-NH-” group on the residue Glu 506 of FAK, and the F-atom on the FPEG chain of  $[^{19}\text{F}]2$  with one “-(C=O)-OH” group on the residue Glu 506 of FAK, respectively.

However, there were only two intermolecular hydrogen bonds between  $[^{19}\text{F}]1$  or  $[^{19}\text{F}]3$  and the kinase domain of FAK. For  $[^{19}\text{F}]1$  and FAK, the hydrogen bonds were formed by one N-atom on the pyrimidine ring of  $[^{19}\text{F}]1$  with one “-NH-” group on the residue Cys 502 of FAK, and the “-NH-” group on the pyrimidine ring of  $[^{19}\text{F}]1$  with the one O-atom on the residue Cys 502 of FAK, respectively. For  $[^{19}\text{F}]3$  and FAK, the hydrogen bonds were formed by one N-atom on the pyrimidine ring of  $[^{19}\text{F}]3$  with one “-NH-” group on the residue Cys 502 of FAK, and the F-atom on the FPEG chain of  $[^{19}\text{F}]2$  with one “-(C=O)-OH” group on the residue Glu 506 of FAK, respectively.

So there were more intermolecular hydrogen bonds between  $[^{19}\text{F}]2$  and the kinase domain of FAK than those between  $[^{19}\text{F}]1$  or  $[^{19}\text{F}]3$  and the kinase domain of FAK, which might also contribute to the significant difference in  $IC_{50}$  values.

## 4. Conclusion

In this study, we prepared two 5-bromo- $N^2$ -(4-(2-fluoropropyl)phenyl)- $N^4$ -(4-methoxyphenyl)-pyrimidine-2,4-diamine derivatives and evaluated them as the F-18 labeled radiotracers targeting FAK for tumor imaging.

The corresponding F-19 standards inhibited the activity of FAK with  $IC_{50}$  values of 57.1 and 1113.6 nM. When the length of the FPEG chain was  $n = 2$ , the interaction between the F-19 standards and the FAK was relatively good, with the  $[^{19}\text{F}]2$  having FAK  $IC_{50}$  of 57.1 nM, which was better than the results in our published work.<sup>22</sup> We also profiled the  $[^{19}\text{F}]2$  *in vitro* against some other kinds of cancer-related kinases, with 62.4 folds selectivity against PYK2, 75.5 folds selectivity against EGFR, and more than 200 folds selectivity against IGF-1R and PDGFR $\beta$ , which were also better than the results in our published work.<sup>22,23</sup>

High *in vitro* stability in normal saline solution and murine plasma were displayed by all the F-18 labeled compounds in this work. Among the two corresponding F-18 labeled compounds in this study, the  $[^{18}\text{F}]2$  with an FPEG chain of medium-length ( $n = 2$ ) were also relatively good with modest tumor uptake of  $5.40 \pm 0.12 \%$  ID per g and  $5.96 \pm 0.09 \%$  ID per g at 15 and 30 min post-injection, respectively, in the studies on biodistribution in S180-tumor-bearing mice, which was also similar to the results in our published work.<sup>22</sup> What's more, its tumor/muscle, tumor/bone and tumor/blood ratio at 15 min post-injection were 2.40, 1.64 and 1.92, respectively. And its tumor/muscle, tumor/bone and tumor/blood ratio at 30 min post-injection were 2.49, 1.55 and 1.94, respectively. In addition, coronal micro-PET images of mice bearing S180 tumor clearly confirmed that  $[^{18}\text{F}]2$  could be obviously accumulated in tumor at 30 min post-injection, which was better than the results of the imaging study in our previous report.<sup>23</sup> Besides, for the  $[^{18}\text{F}]2$ , both the biodistribution data and the micro-PET imaging study showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562271 (one of the reported best selective FAK inhibitor which was developed by Pfizer Inc. and inhibited the activity of FAK with  $IC_{50}$  value of 1.5 nM) at one hour before the injection of radiotracer, indicating that the uptake of  $[^{18}\text{F}]2$  in tumor of the mouse model was due to FAK expression, and that  $[^{18}\text{F}]2$  might be a kind of selectively FAK-targeted tumor imaging agents.

Furthermore, the results of the MD (molecular dynamics) simulations and the docking studies generally consisted with the changing trends of the interaction between the different F-19 standards and the FAK (expressed as the *in vitro* inhibitory abilities of enzymatic activities of FAK in this article), which was also in agreement with and had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor.

Finally, in order to further increase the uptake of the F-18 labeled tracer in tumor, the following points should arouse attention, which could also be considered as the new findings and contributions of this study to the field of tumor imaging agents: (1) the F-18 labeled tumor radiotracers which have



closer interaction with the FAK (namely the stronger FAK inhibitory activity) should be further designed, *via* building of models such as 3D-QSAR model to make reasonable guidance for our drug design, and consideration of some functional groups which have hydrogen-bonding or salt-bridge interactions with key residues in the kinase domain of FAK; (2) the F-18 radiotracers with better pharmacokinetic properties should be designed to improve uptake of the radiotracers in tumor and the speed of clearance from the non-target tissues. Dynamic drug absorption and distribution model in different tissues (such as liver, blood, lung, tumor, *etc.*) should be built, to predict whether the molecules have ideal absorption in tumor and low uptake in non-target tissues, on the basis of the small molecules which have strong interaction with the FAK. The relevant study is being undertaken. These enlightenment may be useful guidance for us to develop better radiotracers for the early diagnosis of cancer.

## Ethical statement

All animal procedures were performed in accordance with Management Regulations of Laboratory Animal of Beijing City, and the Guidelines for Care and Use of Laboratory Animals of Beijing Normal University.

All protocols requiring the use of mice were approved by the Animal Ethics Committee of Beijing Normal University.

## Conflicts of interest

The authors declare no conflict of interest.

## Acknowledgements

This work was supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (Grant No. 2014ZX09507007-001 and 2014ZX09507007-003); the National Science and Technology Support Program (Grant No. 2014BAA03B03) and the National Natural Science Foundation of China (Grant No. 21371026). We thank the Nuclear Medicine Department of Peking Cancer Hospital (Beijing, China) for providing the fluoride-18 nuclide, and also thank the Nuclear Medicine Department of Peking Union Medical College Hospital (Beijing, China) for providing the use of the micro-PET.

## Notes and references

- 1 M. D. Schaller, C. A. Borgma, B. S. Cob, R. R. Vines, A. B. Reynolds and J. T. Parsons, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 5192–5196.
- 2 S. K. Hanks, M. B. Calalb, M. C. Harper and S. K. Patel, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 8487–8491.
- 3 P. Dao, N. Smith, C. Tomkiewicz-Raulet, E. Yen-Pon, M. Camacho-Artacho, D. Lietha, J. P. Herbeauval, X. Coumoul, C. Garbay and H. Chen, *J. Med. Chem.*, 2015, **58**, 237–251.
- 4 D. Lietha and M. J. Eck, *PLoS One*, 2008, **3**, e3800.
- 5 W. G. Roberts, E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E. Emerson, J. Lin, J. Kath, K. Coleman, L. Yao, L. Martinez-Alsina, M. Lorenzen, M. Berliner, M. Luzzio, N. Patel, E. Schmitt, S. LaGreca, J. Jani, M. Wessel, E. Marr, M. Griffor and F. Vajdos, *Cancer Res.*, 2008, **68**, 1935–1944.
- 6 P. Dao, R. Jarray, J. L. Coq, D. Lietha, A. Loukaci, Y. Lepelletier, R. Hadj-Slimane, C. Garbay, F. Raynaud and H. Chen, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 4552–4556.
- 7 T. Heinrich, J. Seenisamy, L. Emmanuel, S. S. Kulkarni, J. Bomke, F. Rohdich, H. Greiner, C. Esdar, M. Krier, U. Gradler and D. Musil, *J. Med. Chem.*, 2013, **56**, 1160–1170.
- 8 J. Zhang and S. N. Hochwald, *Pharmacol. Ther.*, 2014, **142**, 154–163.
- 9 W. G. Cance, E. Kurenova, T. Marlowe and V. Golubovskaya, *Sci. Signaling*, 2013, **6**, 10.
- 10 T. Lechertier and K. Hodivala-Dilke, *J. Pathol.*, 2012, **226**, 404–412.
- 11 W. W. Ma, *Anticancer Agents Med. Chem.*, 2011, **11**, 638–642.
- 12 W. G. Cance, J. E. Harris, M. V. Iacocca, E. Roche, X. Yang, J. Chang, S. Simkins and L. Xu, *Clin. Cancer Res.*, 2000, **6**, 2417–2423.
- 13 G. W. McLean, N. O. Carragher, E. Avizienyte, J. Evans, V. G. Brunton and M. C. Frame, *Nat. Rev. Cancer*, 2005, **5**, 505–515.
- 14 V. M. Golubovskaya, F. A. Kweh and W. G. Cance, *Histol. Histopathol.*, 2009, **24**, 503–510.
- 15 N. A. Chatzizacharias, G. P. Kouraklis and S. E. Theocaris, *Expert Opin. Ther. Targets*, 2007, **11**, 1315–1328.
- 16 E. K. Han and T. McGonigal, *Anticancer Agents Med. Chem.*, 2007, **7**, 681–684.
- 17 M. J. van Nimwegen and B. van de Water, *Biochem. Pharmacol.*, 2007, **73**, 597–609.
- 18 V. M. Golubovskaya, *Anticancer Agents Med. Chem.*, 2010, **10**, 735–741.
- 19 A. Schultze and W. Fiedler, *Expert Opin. Invest. Drugs*, 2010, **19**, 777–788.
- 20 V. M. Golubovskaya, *Front. Biosci.*, 2014, **19**, 687–706.
- 21 A. Schultze and W. Fiedler, *Anti-Cancer Agents Med. Chem.*, 2011, **11**, 593–599.
- 22 Y. Fang, D. Wang, X. Xu, J. Liu, A. Wu, X. Li, Q. Xue, H. Wang, H. Wang and H. Zhang, *Eur. J. Med. Chem.*, 2017, **127**, 493–508.
- 23 D. Wang, Y. Fang, H. Wang, X. Xu, J. Liu and H. Zhang, *RSC Adv.*, 2017, **7**, 22388–22399.
- 24 (a) R. Francois, S. Lu, D. He, M. Zajac-Kaye and S. A. Hochwald, *Eur. J. Cancer*, 2002, **48**, S174; (b) S. F. Jones, G. Shapiro, J. C. Bendell, E. X. Chen, P. Bedard, J. M. Cleary, S. Pandya, K. J. Pierce, B. Houk, N. Hosea, K. S. Zandi, W. G. Roberts, S. M. Shreeve and L. L. Siu, *J. Clin. Oncol.*, 2011, **29**, 3002.
- 25 V. M. Golubovskaya, B. Ho, M. Zheng, A. Magis, D. Ostrov, C. Morrison and W. G. Cance, *BMC Cancer*, 2013, **13**, 342–346.
- 26 K. R. Auger, K. N. Smitheman, S. Korenchuk, C. McHugh, R. Kruger, G. S. Van Aller, A. Smallwood, R. R. Gontarek, T. Faitg and N. Johnson, *Eur. J. Cancer*, 2012, **4**, 118.



27 V. M. Golubovskaya, C. Nyberg, M. Zheng, F. Kweh, A. Magis, D. Ostrov and W. G. Cance, *J. Med. Chem.*, 2008, **51**, 7405–7416.

28 (a) M. Iwatani, H. Iwata, A. Okabe, R. J. Skene, N. Tomita, Y. Hayashi, Y. Aramaki, D. J. Hosfield, A. Hori, A. Baba and H. Miki, *Eur. J. Med. Chem.*, 2012, **61**, 49–60; (b) N. Tomita, Y. Hayashi, S. Suzuki, Y. Oomori, Y. Aramaki, Y. Matsushita, M. Iwatani, H. Iwata, A. Okabe, Y. Awazu, O. Isono, R. J. Skene, D. J. Hosfield, H. Miki, T. Kawamoto, A. Hori and A. Bab, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 1779–1785.

29 E. V. Kurenova, D. L. Hunt, D. He, A. T. Magis, D. A. Ostrov and W. G. Cance, *J. Med. Chem.*, 2009, **52**, 4716–4724.

30 (a) D. A. Ucar, E. Kurenova, T. J. Garrett, W. G. Cance, C. Nyberg, A. Cox, N. Massoll, D. A. Ostrov, N. Lawrence, S. M. Sebti, M. Zajac-Kaye and S. N. Hochwald, *Cell Cycle*, 2012, **11**, 3250–3259; (b) D. A. Ucar, A. T. Magis, D. H. He, N. J. Lawrence, S. M. Sebti, E. Kurenova, M. Zajac-Kaye, J. Zhang and S. N. Hochwald, *Anticancer Agents Med. Chem.*, 2013, **13**, 595–602.

31 V. Golubovskaya, N. L. Palma, M. Zheng, B. Ho, A. Magis, D. Ostrov and W. G. Cance, *Anticancer Agents Med. Chem.*, 2013, **13**, 532–545.

32 T. Liu, T. LaFortune, T. Honda, O. Ohmori, S. Hatakeyama, T. Meyer, D. Jackson, J. de Groot and W. Yung, *Mol. Cancer Ther.*, 2007, **6**, 1357–1367.

33 J. Xu, H. Liu, G. Li, Y. He, R. Ding, X. Wang, M. Feng, S. Zhang, Y. Chen, S. Li, M. Zhao, Y. Li, C. Qi and Y. Dang, *Molecules*, 2012, **17**, 3774–3793.

